Hormonal substitution therapy in risk nononcologic patient
Authors:
M. Petzel; Peter Koliba; O. Šimetka
Authors‘ workplace:
Porodnicko-gynekologická klinika FNsP Ostrava
Published in:
Prakt Gyn 2005; 9(4): 26-28
Overview
The conditions of estrogen deficiency may lead to a significant quality of life decrease. Hormonal substitution therapy (HST) leads to the reduction of acute and chronic complaints related to the perimenopausal and postmenopausal periods. The problem in daily practice are the women with the risk factors present, which require the consideration of absolute and relative contraindications during treatment decision-making. If the risk factors and relative contraindications are present, it is necessary to consider their seriousness and individually evaluate the therapy benefit in comparison with the measure of the related risk. At the beginning of the therapy there must be excluded the occurence of the states which are absolutely contraindicated to HST.
Key words:
hormonal substitution therapy – risk patients
Sources
1. Goodslan IF, Gaugar KF et al. Carbohydrate metabolism as a cardiovascular disease risc factor – its relation to menopause and hormone replacement therapy: Cardiovascular disease and hormone replacement therapy. XIII th world congress of Gynaecology and Obstetrics, Singapure, september 1991.
2. Nappi RE, Cagnacci A, Granella F et al. Course of primary headaches during hormone replacement therapy. Maturitas 2001; 38: 157-163.
3. Chamberlain MC. Meningeomas, Current treatment options. Neurol 2001; 3: 67-76.
4. Kenemans P, Barentsen D, Van de Weijer P. Practical HRT. Zeist: Medical forum international 1996: 61-83.
5. Jick H, Derby LE, Myers MW, Vasilakis C, Newton KM. Risk of hospital admission for idiopathic venous thromboembolism among users of postmenopausal oestrogens. Lancet 1996; 348: 981-983.
6. Devor M, Barrett-Connor E, Renvall M, Feigal D, Ramsdell J. Estrogen replacement therapy and the risk of venous thrombosis. Am J Med 1992; 92: 275-282.
7. Guthann PS, Rodriguez LAG, Castellsague J, Oliart AS. Hormone replacement therapy and risk of venous thrombembolism: population – based case control study. BMJ 1997; 314: 796-800.
8. Daly E, Edel D, Vessey MP, Martin P et al. Risk of venous thromboembolism in users of hormone replacement therapy. The Lancet 1996; 348(9033): 997-980.
9. Marcelo PV, Gomes MD, Steven R, Deitcher MD. Risk of Vernous thrombembolic Disease Assiciated With hormonal Contraceptives and Hormone Replacement Therapy. Archives of internal medicíně 2004; 164(18): 1965.
10. The Women´s health initiative Steerin comitee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy. The women health initiative Randomized controled trial. JAMA 2004; 291: 1701-1712.
11. Grady D, Rubin SM et al. Hormone replacement therapy to present disease and prolong life in postmenopausal women. Ann Intern Med 1992; 117: 1016.
12. Grodstein F, Stampfer MJ et al. Postmenopausal hormone therapy and mortality. N Engl J Med 1997; 336: 1949.
13. Bush T, Miller-Bass K. Estrogen therapy and cardiovascular didease: do the benefit outweight the risks? Clin Obst Gynecol 1991; 5: 889.
14. Stampfer MJ, Golditz GFA. Estrogen replacement therapy and cronary heart disease: A quantiotative asssesnebt of the epidemiologic evidence. Prev Med 1991; 20: 47.
15. Hulley S, Grady D et al. Randomized Trial of Estrogen Plus Progestin for Secondary prevention of Coronary Heart Disease in Postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research group. JAMA 1998; 280: 605.
16. Lowe GO, Upton MN, Rumley A et al. Different effects of oral and transdermal hormone replacement therapy on Factor IX, APC resistance, t-PA, PAI and C-reactive Protein. Tromb Haemost 2001; 86: 550-556.
17. The Esprit team. Estrogen therapy for prevention of reinfarction in postmenopausal women: a randomized placebo controlled trial. Lancet 2002; 360: 2001.
18. Mercuro G, Zoncu S et al. Estradiol 17 beta reduces blood pressure and restores the normal amplitude of the circadian blood pressure rhytm in postmenopausal hypertension. Am J Hyperens 1998; 11: 909.
19. Viscoli CM, Brass LM, Kermann WN et al. A clinical trial of estrogen – replacement therapy after ischemic stroke. The New England Journal of Medicine 2001; 345(17): 1243-1250.
20. Herrington DM, Vittinghoff E, Howard TD et al. Factor V Leiden, hormone replacement therapy, and risk of venous thromboembolic events in women with coronary disease. Arteroscler Thromb Vasc Biol 2002; 22: 1012-1017.
21. Rosendaal FR, Vessey M, Rumley A et al. Hormone replacement therapy, prothrombic mutations and the risk of venous thrombosis. Br J Haematol 2002; 116: 851-854.
22. Schlipak MG, Angeja BG et al. Hormone replacement therapy and in – hospital survivor after myocardical infarctionin postmenopausal women. Circulation 2001; 104: 2300.
Labels
Paediatric gynaecology Gynaecology and obstetrics Reproduction medicineArticle was published in
Practical Gynecology
2005 Issue 4
Most read in this issue
- Clinical experiences with low-dose hormone replacement therapy
- Epilepsy in pregnancy
- ST analysis of fetal ECG curve during parturition
- Clinial meaning of hyperprolactinemy